Se prevé que el mercado de radiofármacos alcance los 13.818,17 millones de dólares en 2028, frente a los 7.550,74 millones de dólares de 2021; se espera que crezca a una tasa compuesta anual del 9,0% de 2021 a 2028.
El crecimiento del mercado se atribuye a la creciente prevalencia de enfermedades crónicas, la idoneidad de la radioinmunoterapia alfa en objetivos tratamiento del cáncer y avances en las técnicas de imágenes nucleares. Sin embargo, la corta vida útil de los radiofármacos y la disponibilidad de sustitutos frenan el crecimiento del mercado de radiofármacos. Un radiofármaco es un fármaco que puede utilizarse con fines diagnósticos o terapéuticos. Los radiofármacos son radioisótopos que están unidos a moléculas biológicas que se dirigen a tejidos, órganos o células específicos del cuerpo humano. Los radioisótopos que emiten rayos gamma son útiles para el diagnóstico por imágenes cuando la radiación escapa del cuerpo. Estos rayos se detectan mediante un dispositivo específico, que suele ser una cámara de tomografía computarizada por emisión de fotón único (SPECT)/tomografía por emisión de positrones (PET).
La pandemia de COVID-19 ha cambiado profundamente las actividades hospitalarias, incluida la nuclear. prácticas de medicina (NM) en toda Europa. Se realizó una búsqueda bibliográfica en PubMed que cubría los estudios de COVID-19 publicados hasta enero de 2021. Según los hallazgos, la pandemia desafió fuertemente a los departamentos de Nuevo México y se ha experimentado una reducción de la fuerza laboral en todos los centros de Europa. Para limitar la transmisión de COVID-19, los departamentos de Nuevo México introdujeron medidas de restricción, como la reprogramación de procedimientos que no son de alta prioridad. Además, algunos de los departamentos experimentaron un retraso en el suministro de radiofármacos o asistencia técnica debido a la pandemia. Como resultado, la crisis se tradujo en una reducción significativa de los procedimientos diagnósticos y terapéuticos de MN y en un nivel reducido de atención a los pacientes afectados por enfermedades como el cáncer o las enfermedades cardiovasculares agudas.
regiones lucrativas para el mercado de radiofármacos< br>Perspectivas del mercado
La creciente prevalencia de enfermedades crónicas impulsa el crecimiento del mercado de radiofármacos
La prevalencia de enfermedades crónicas como las enfermedades cardiovasculares (ECV), El cáncer, las enfermedades pulmonares crónicas, los accidentes cerebrovasculares, la enfermedad de Alzheimer, la enfermedad renal crónica y varios trastornos neurológicos están aumentando rápidamente en todo el mundo. Estas enfermedades se encuentran entre las principales causas de muerte. Según la Organización Mundial de la Salud (OMS), el cáncer representó 10 millones de muertes en 2020 en todo el mundo. Además, según las estimaciones de la Sociedad Estadounidense del Cáncer, en 2020 se diagnosticaron 1.806.590 nuevos casos de cáncer en los EE. UU. Según la Red Europea del Corazón, las ECV causan 3,9 millones de muertes en Europa y más de 1,8 millones de muertes en la Unión Europea ( UE) cada año. Representan el 45,0% del total de mortalidades en Europa y el 37,0% del total de muertes en la UE. Según el Colegio Americano de Cardiología, las enfermedades cardiovasculares causan 800.000 casos de muerte en los EE. UU. cada año. La enfermedad coronaria (CHD) contribuye a la mayoría de las muertes por ECV, seguida por los accidentes cerebrovasculares y la insuficiencia cardíaca; Cada año, 90 millones de estadounidenses son diagnosticados con enfermedades cardiovasculares. Además, las enfermedades cardiovasculares contribuyen al 31 % del total de muertes a nivel mundial, y se espera que la carga de costos de las enfermedades cardiovasculares en los sistemas de salud sea de 1.044 mil millones de dólares para 2030.
Según Emory Healthcare, en 2018, 5 millones personas sufren de insuficiencia cardíaca congestiva (ICC) en los EE. UU. Además, según la OMS, ~1,71 mil millones de personas en el mundo padecen afecciones musculoesqueléticas. Un examen eficaz es imprescindible para el tratamiento de enfermedades crónicas, y se utilizan sustancias nucleares con fines de diagnóstico y examen; se utilizan en pruebas de diagnóstico como la tomografía por emisión de positrones (PET) y la tomografía computarizada por emisión de fotón único (SPECT). Por lo tanto, con un aumento en la incidencia de enfermedades crónicas, la necesidad de radiofármacos también está aumentando, impulsando así el crecimiento del mercado.
Información basada en tipos
Según el tipo, los radiofármacos El mercado se divide en medicina nuclear de diagnóstico y medicina nuclear terapéutica. El segmento de medicina nuclear de diagnóstico tiene una mayor participación de mercado y se espera que registre una CAGR más alta durante 2021-2028. El radioisótopo utilizado ampliamente en medicina nuclear de diagnóstico es el tecnecio-99m. El radioisótopo se adhiere a varias moléculas específicas, lo que permite el diagnóstico de diversas enfermedades, como ciertos tipos de cáncer. Por ejemplo, el tecnecio-99m-MDP (difosfonato de metileno) se usa ampliamente para detectar metástasis óseas asociadas con el cáncer.
Información basada en el tipo de producto
Según el tipo de producto, el mercado de radiofármacos se segmenta en tecnecio-99m, talio-201 y galio-67. , Yodo-131, Cobre-64 y otros. El segmento de tecnecio-99m tiene la mayor participación del mercado, mientras que se espera que el segmento de galio-67 registre la CAGR más alta durante 2021-2028. El galio-67 se utiliza para la obtención de imágenes y la localización de lesiones inflamatorias (infecciones). El galio-67 es un radiofármaco inyectable que se utiliza con tomografía computarizada por emisión de fotón único (SPECT) para detectar la presencia de lesiones inflamatorias agudas y diversas neoplasias malignas, como la enfermedad de Hodgkin, linfomas y carcinomas broncogénicos.
Información basada en aplicaciones
Según la aplicación, el mercado de radiofármacos se segmenta en oncología, cardiología, neurología y otros. El segmento de oncología tiene la mayor participación del mercado. El crecimiento del mercado para este segmento se puede atribuir a la creciente incidencia del cáncer en todo el mundo. El cáncer es uno de los problemas de salud importantes con una alta tasa de mortalidad. Es una amenaza para la salud global. Según la OMS, en 2018 se diagnosticaron aproximadamente 18 millones de nuevos casos de cáncer en todo el mundo y 9,6 millones de personas murieron a causa de este cáncer. Sin embargo, se espera que el mercado del segmento de cardiología crezca al ritmo más rápido en los próximos años.
Información basada en el usuario final
Basada en el usuario final , el mercado de radiofármacos se segmenta en hospitales, centros de imágenes, centros académicos y de investigación, entre otros. En 2021, el segmento de hospitales tendrá la mayor participación del mercado. El crecimiento del mercado para este segmento se puede atribuir a la creciente prevalencia de enfermedades crónicas, el creciente número de hospitales en todo el mundo y el rápido crecimiento del número de procedimientos quirúrgicos. Sin embargo, se espera que el mercado del segmento de centros de diagnóstico crezca al ritmo más rápido en los próximos años.
Perspectivas estratégicas
Las empresas que operan en el mercado de radiofármacos están adoptando el estrategia de innovación de productos para satisfacer las cambiantes demandas de los clientes en todo el mundo, lo que también les permite mantener su marca en el mercado global.
Mercado de radiofármacos: por tipo
- Medicina nuclear de diagnóstico
- Radiofármacos SPECT
- Radiofármacos PET
- Radiofármacos terapéuticos Medicina
- Emisores alfa
- Emisores beta
- Isótopos de braquiterapia
Mercado de radiofármacos: mercado de productos farmacéuticos por tipo de producto
- Tecnecio-99m
- Talio-201
- Galio-67
- Yodo-131
- Cobre-64
- Otros
Mercado de radiofármacos – ndash; por aplicación
- Oncología
- Cardiología
- Neurología
- Otros
Mercado de radiofármacos - por usuario final
- Hospitales
- Centros de imágenes
- Centros académicos y de investigación
- Otros
Mercado de radiofármacos: por Geografía
- América del Norte
- Estados Unidos
- Canadá
- México
< li>Europa - Francia
- Alemania
- Italia
- Reino Unido
- España
- Resto de Europa
- Asia Pacífico (APAC)
- China
- India
- Corea del Sur
- Japón
- Australia
- Resto de APAC
- Oriente Medio y África (MEA)
- Sudáfrica
- Arabia Saudita
- EAU
- Resto de MEA
- América del Sur y Central (SCAM )
- Brasil
- Argentina
- Resto de ESTAFA
Perfiles de Empresas
- Cardinal Health
- GE Healthcare
- Curium
- Lantheus Medical Imaging
- Bayer AG < li>Imágenes de Bracco
- Eczacýbaþý-Monrol Nuclear Products
- Nordion
- Aplicaciones avanzadas de aceleradores
- Radioisótopos NTP
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Radiopharmaceuticals are radioisotopes that are bound to biological molecules that target specific tissues, organs, or cells within the human body. Radioisotopes emitting gamma rays are useful for diagnostic imaging where the radiation escapes the body. These rays are detected by a specific device, which is usually single-photon emission computed tomography (SPECT)/ positron emission tomography (PET) cameras.
The factors that are driving growth of the market are rising prevalence of chronic diseases, suitability of alpha radioimmunotherapy in targeted cancer treatment, and advancements in nuclear imaging techniques.
Various companies have made organic growth strategies in the Radiopharmaceuticals Market. Some of the activities undertaken by the company, which have promoted its growth are, launches, enhancements and expansion & relocation activities. Companies such as Lantheus Medical Imaging, Inc., Bracco Imaging S.p.A, Advanced Accelerator Applications amongst others are some of the companies that have been implementing various organic strategies that have helped the growth of the company.
North America dominates the global radiopharmaceuticals market due to factors such as technological advancement, increasing product launches, well-developed healthcare facility centres equipped with modern-age equipment and instruments.
The diagnostic nuclear medicine segment is growing at the highest CAGR owing to availability of diagnostic devices and ease offered by these devices for diagnosis of various disorders. Also, nuclear medicine provides better diagnostic information about the functioning of a specific organ, as it uses radiation.
Asia Pacific is expected to be the fastest growing region in the radiopharmaceuticals market. The growth of the market in this region is primarily due to prevalence of stroke and other neurological disorders along with the presence of supportive government initiatives and research in the field of radiopharmaceuticals.
The List of Companies - Radiopharmaceuticals Market
- Cardinal Health
- GE Healthcare
- Curium
- Lantheus Medical Imaging
- Bayer AG
- Bracco Imaging
- Eczacýbaþý-Monrol Nuclear Products
- Nordion
- Advanced Accelerator Applications
- NTP Radioisotopes
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Aug 2021
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2021
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Aug 2021
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Aug 2021
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2021
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2021
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Aug 2021
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Aug 2021
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)